Rein Therapeutics, Inc.
No SEC Form 4 filings for $RNTX in the last 30 days.
See all $RNTX insider activity →Rein Therapeutics (RNTX) had $41M in cash and no debt as of June 2026, with a cash burn of $19M, giving it a 2.2-year runway. The company's cash burn decreased by 11%, and its market cap is $73M. While its cash burn relative to market cap is notable, its runway is considered promising.
Rein Therapeutics (RNTX) received FDA Fast Track designation for LTI-03, a treatment for idiopathic pulmonary fibrosis. The therapy aims to inhibit lung scarring and preserve tissue repair cells. RNTX is conducting a Phase 2 trial with interim data expected in late 2026. The stock closed at $0.79, up 2.84%, and was at $0.80 in pre-market trading.
Rein Therapeutics, Inc. (RNTX) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. 8-K NASDAQ false 0001420565 0001420565 2026-07-20 2026-07-20 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July
Over the past 7 days, alphai's AI scored 1 news story mentioning RNTX (Rein Therapeutics, Inc.). Coverage has been balanced: 0 bullish, 1 neutral, and 0 bearish.
Recent RNTX coverage spans financial news, regulation and corporate actions.
The disclosed cash runway suggests limited short‑term liquidity risk but potential dilution if additional capital is needed.
Fast Track status may accelerate approval and boost investor confidence.
The disclosed vote results confirm governance actions (board seats, share authorization expansion) but do not provide new operating or financial guidance.
U.K. site activation and continued enrollment expansion reduce execution risk for the Phase 2 program and may support near-term sentiment for RNTX’s LTI-03 timeline.
This is a small-to-moderate insider buy that may support near-term sentiment, but it is not a fundamental catalyst by itself.
alphai scores every news story that mentions RNTX with an AI model for sentiment and relevance, and aggregates insider trades from Rein Therapeutics, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Rein Therapeutics (RNTX) had $41M in cash and no debt as of June 2026, with a cash burn of $19M, giving it a 2.2-year runway. The company's cash burn decreased by 11%, and its market cap is $73M. While its cash burn relative to market cap is notable, its runway is considered promising.
2 min readRein Therapeutics (RNTX) received FDA Fast Track designation for LTI-03, a treatment for idiopathic pulmonary fibrosis. The therapy aims to inhibit lung scarring and preserve tissue repair cells. RNTX is conducting a Phase 2 trial with interim data expected in late 2026. The stock closed at $0.79, up 2.84%, and was at $0.80 in pre-market trading.
2 min readRein Therapeutics, Inc. (RNTX) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. 8-K NASDAQ false 0001420565 0001420565 2026-07-20 2026-07-20 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July
2 min readRein Therapeutics (NASDAQ: RNTX) said it has expanded its Phase 2 RENEW trial of inhaled peptide LTI-03 for idiopathic pulmonary fibrosis into the United Kingdom, with the first U.K. patient randomized. The company reported 16 patients enrolled to date. Trial sites are enrolling in the U.S., Australia, and the U.K., with two additional countries expected to add sites soon.
4 min readVON RICKENBACH JOSEF H purchased 47,060 shares of Rein Therapeutics, Inc. (RNTX) at an average of $1.05 ($1.04–$1.07) across 4 trades over 2026-05-21 to 2026-05-27.
1 min readRein Therapeutics ( NASDAQ:RNTX ) stock is trading higher on Monday, with a session volume of 41.2 million compared to its average volume of 162.67 thousand, according to data from Benzinga Pro. What Happened: The U.S.
2 min readRein Therapeutics Receives FDA Clearance to Resume U.S. Phase 2 Trial of ...
2 min readPeer-reviewed publication highlights potential breakthrough anti-fibrotic properties of LTI-03 in lung tissue from IPF patients ...
3 min readAUSTIN, Aug. 19, 2025 ( GLOBE NEWSWIRE ) -- Rein Therapeutics ( "Rein" ) ( NASDAQ: RNTX ) , a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis indications, today announced that the UK ...
3 min readAUSTIN, Texas, Aug. 14, 2025 ( GLOBE NEWSWIRE ) -- Rein Therapeutics ( "Rein" ) RNTX, a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis indications, announced that Chief Scientific ...
2 min read
